Marc Oliva

Institut Català d'Oncologia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ricard Mesı́a

Institut Català d'Ornitologia

Lillian L. Siu

Princess Margaret Cancer Centre

Anna Spreafico

Princess Margaret Cancer Centre

Miren Taberna

Institut Català d'Oncologia

A. Lozano

Institut Català d'Oncologia

Lorena Arribas

Institut Català d'Oncologia

Aaron R. Hansen

Princess Margaret Cancer Centre

J. Brenes Castro

Institut Català d'Oncologia

Scott V. Bratman

Princess Margaret Cancer Centre

Bryan Coburn

University of Toronto

Cooperative Institutions

Institut Català d'Oncologia

148

Institut d'Investigació Biomédica de Bellvitge

115

Princess Margaret Cancer Centre

University of Toronto

University Health Network

Bellvitge University Hospital

Universitat de Barcelona

Duran i Reynals Hospital

Institut Català d'Ornitologia

Universitat Autònoma de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

Head & Neck (2016)

Aleix Rovira Jordi Tornero Marc Oliva Miren Taberna Robert Montal

Abstract Background The purpose of this study was to describe the results and complications of primary site salvage surgery after head and neck squamous cell carcinoma (HNSCC) treated with bioradiotherapy. Methods We conducted a retrospective chart review of 268 patients treated with bioradiotherapy between March 2006 and December 2013 at the Hospital Universitari de Bellvitge‐ICO. Results Fifty‐nine patients developed local recurrence or had residual disease with a 1‐year and 3‐year overall survival of 47% and 15.4%, respectively. Salvage surgery was feasible in 22 patients (37.3%). There were 16 complications in these 22 patients (72.7%), 11 (50%) of which were major. Bilateral neck dissection was identified as a risk factor for complications. Conclusion Salvage surgery after bioradiotherapy is associated with a high rate of complications. Neck dissection seems to be related to an increased rate of complications with no survival improvement. © 2016 Wiley Periodicals, Inc. Head Neck 39: 116–121, 2017

Salvage Surgery

Neck dissection

10.1002/hed.24549

Cite

Citations (9)

P-044 Preoperative chemoradiotherapy in locally advanced esophageal carcinoma. A retrospective study from a multidisciplinary oncologic centre

Annals of Oncology (2015)

María Saigi Marc Oliva Òlbia Serra Leandre Farràn M. Calvo

Esophagectomy

Chemoradiotherapy

Regimen

10.1093/annonc/mdv233.44

Cite

Citations (0)

Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing

mSystems (2021)

Matthew Y. Cho Marc Oliva Anna Spreafico Bo Chen Wei Xu

When determining human microbiota composition, shotgun sequencing is a powerful tool that can generate high-resolution taxonomic and functional information at once. However, the technique is limited by missing information about host-to-microbe ratios observed in different body compartments. This limitation makes it difficult to plan shotgun sequencing assays, especially in the context of high sample multiplexing and limited sequencing output and is of particular importance for studies employing the recently described shallow shotgun sequencing technique. In this study, we evaluated the use of a quantitative PCR (qPCR)-based assay to predict host-to-microbe ratio prior to sequencing. Combining a two-target assay involving the bacterial 16S rRNA gene and the human beta-actin gene, we derived a model to predict human-to-microbe ratios from two sample types, including stool samples and oropharyngeal swabs. We then validated it on two independently collected sample types, including rectal swabs and vaginal secretion samples. This assay enabled accurate prediction in the validation set in a range of sample compositions between 4% and 98% nonhuman reads and observed proportions varied between -18.8% and +19.2% from the expected values. We hope that this easy-to-use assay will help researchers to plan their shotgun sequencing experiments in a more efficient way. IMPORTANCE When determining human microbiota composition, shotgun sequencing is a powerful tool that can generate large amounts of data. However, in sample compositions with low or variable microbial density, shallowing sequencing can negatively affect microbial community metrics. Here, we show that variable sequencing depth decreases measured alpha diversity at differing rates based on community composition. We then derived a model that can determine sample composition prior to sequencing using quantitative PCR (qPCR) data and validated the model using a separate sample set. We have included a tool that uses this model to be available for researchers to use when gauging shallow sequencing viability of samples.

Shotgun

10.1128/msystems.00552-21

Cite

Citations (5)

2220P MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma

Annals of Oncology (2023)

N. Baste Rotllan Jorge Hernando Javier Martínez‐Trufero M. Plana Serrahima J. Rubió-Casadevall

10.1016/j.annonc.2023.09.999

Cite

Citations (0)

928P Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)

Annals of Oncology (2023)

Z. Vidales Sepulveda M. Choulli S. Fabrego Natàlia Pallarès Natacha Santos

10.1016/j.annonc.2023.09.2072

Cite

Citations (0)

Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009

Clinical Cancer Research (2023)

Kevin J. Harrington Hye Ryun Kim Sébastien Salas Marc Oliva Robert Metcalf

Abstract Introduction: Pembrolizumab monotherapy and pembrolizumab plus platinum-based chemotherapy are the standard of care for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Pembrolizumab plus lenvatinib showed promising antitumor activity and manageable safety in metastatic HNSCC in the phase 1b/2 Study 111/KEYNOTE-146 trial. The randomized, open-label, phase 2 LEAP-009 (NCT04428151) study is designed to evaluate the safety and efficacy of lenvatinib plus pembrolizumab or lenvatinib monotherapy versus chemotherapy in R/M HNSCC upon progression after treatment with platinum-based therapy and a PD-1/L1 inhibitor. Materials and Methods: Eligible patients have locally incurable, histologically confirmed R/M HNSCC (of the oral cavity, oropharynx, hypopharynx, and/or larynx), ECOG PS of 0 or 1, no ulceration and/or fungation of disease on skin, and disease progression on or after platinum-based therapy (with/without cetuximab) and PD-1/L1 inhibitor (progression must be within 12 weeks from last dose and patients must have received ≥2 doses). Patients will be randomly assigned 3:3:2 to receive oral lenvatinib 20 mg every day plus pembrolizumab 200 mg IV every 3 weeks (≤35 pembrolizumab cycles), standard-of-care chemotherapy (investigator’s choice of docetaxel, paclitaxel, cetuximab, or capecitabine), or oral lenvatinib monotherapy 24 mg every day. Treatment will continue until centrally verified disease progression, unacceptable toxicity, or withdrawal. Patients who experience centrally verified disease progression in chemotherapy or lenvatinib monotherapy arms may cross over to lenvatinib plus pembrolizumab at time of disease progression with sponsor consultation. Randomization will be stratified by PD-L1 tumor proportion score (<50% vs ≥50%) and ECOG PS (0 vs 1). Imaging will be performed every 6 weeks through year 1 and every 9 weeks thereafter. Response will be assessed per RECIST v1.1 by blinded independent central review. Safety will be monitored throughout the study and for 30 days following treatment end (90 days for serious AEs) and graded per NCI CTCAE v5.0. The primary end point is objective response rate and secondary end points are progression-free survival, duration of response, overall survival, and safety. Results: Planned enrollment is approximately 400, and recruitment is currently underway in Asia, Australia, Europe, and North America. Conclusion: Results of LEAP-009 will provide clarity on the efficacy and safety of lenvatinib with or without pembrolizumab versus chemotherapy for patients with R/M HNSCC upon progression after platinum and immunotherapy. Citation Format: Kevin J. Harrington, Hye Ryun Kim, Sebastien Salas, Marc Oliva, Robert Metcalf, Mogens Bernsdorf, Ji-Won Kim, Ezra E. W. Cohen, Lillian Siu, Danny Rischin, Lisa Licitra, Jan Vermorken, Quynh Le, Makoto Tahara, Jean-Pascal Machiels, Karen O'Hara, Kumudu Pathiraja, Burak Gumuscu, Behzad Bidadi, Barbara Burtness. Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009 [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-003.

Lenvatinib

10.1158/1557-3265.aacrahns23-po-003

Cite

Citations (0)

1002P Impact of pharmacodynamic biomarkers in phase I immune-oncology trials

Annals of Oncology (2021)

Abdulazeez Salawu Ruizhe Chen A. Hernando Calvo Daniel Vilarim Araújo Marc Oliva

Pharmacodynamics

10.1016/j.annonc.2021.08.1386

Cite

Citations (0)

949P Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy

Annals of Oncology (2020)

Nieves Plana Guido Cefarelli P Guillén Anna Esteve Marc Oliva

10.1016/j.annonc.2020.08.1064

Cite

Citations (2)

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Annals of Oncology (2019)

M.O. Ochoa de Olza Marc Oliva C. Hierro I. Matos J. Martin-Liberal

Ann Oncol 2018; 29: 1727–1740 (doi: 10.1093/annonc/mdy225) The funding statement has been corrected to read “This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI) supported by the Banco Bilbao Vizcaya Argentaria Foundation (FBBVA) (grant 89/2017).” Early-drug development in the era of immuno-oncology: are we ready to face the challenges?Annals of OncologyVol. 29Issue 8PreviewThe classical development of drugs has progressively faded away, and we are currently in an era of seamless drug-development, where first-in-human trials include unusually big expansion cohorts in the search for early signs of activity and rapid regulatory approval. The fierce competition between different pharmaceutical companies and the hype for immune combinations obliges us to question the current way in which we are evaluating these drugs. In this review, we discuss critical issues and caveats in immunotherapy development. Full-Text PDF Open Archive

Drug Development

Annals

Drug approval

10.1093/annonc/mdz211

Cite

Citations (3)

A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

Annals of Oncology (2019)

Anna Spreafico Filip Janků J. Rodon A. W. Tolcher Sreenivasa R Chandana

10.1093/annonc/mdz253.023

Cite

Citations (11)